Late night surge! The renminbi and A50 rose, and China concept stocks rose across the board, while gold and silver soared.

Tonight, the U.S. June CPI data was released, showing that inflation in the United States has cooled across the board.

Securities TimesJul 11 22:06

Bank of America Securities downgrades Beigene (06160.HK) target price to HKD 92.09, rating 'neutral'.

Bank of America Securities research report pointed out that Beigene's (06160.HK) independently developed BTK inhibitors zanubrutinib, orelabrutinib, ibrutinib, and acalabrutinib recorded sales of RMB 60.9 million, 26.8 million, 25.3 million, and 0.3 million yuan respectively in May, accounting for 53.7%, 23.7%, 22.3%, and 0.3% of the overall sales in the mainland market. The bank lowered its 2024 forecast due to the updated sales data and intensified competition in the mainland BTK inhibitor market.

AASTOCKSJul 10 10:16

BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A Securities

BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A

Dow JonesJul 10 01:30

BeiGene Is Maintained at Neutral by B of A Securities

BeiGene Is Maintained at Neutral by B of A

Dow JonesJul 10 01:30

B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5

B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $152.5.

BenzingaJul 10 01:20

BeiGene Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 5.92% B of A Securities $180 → $152.5 Maintains Neutral 05/09/2024 76.43% TD Cowen $236 → $254

BenzingaJul 10 01:19